Ken Griffin Avadel Pharmaceuticals PLC Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$12.55 - $17.22 $11.9 Million - $16.4 Million	950,705 Added 155.04%	1,563,890 $26.4 Million
Q4 2023 Feb 14, 2024	BUY	$9.64 - $14.59 $1.45 Million - $2.19 Million	150,080 Added 32.41%	613,185 $8.66 Million
Q3 2023 Nov 14, 2023	SELL	$10.3 - $15.99 $237,827 - $369,209	-23,090 Reduced 4.75%	463,105 $4.77 Million
Q2 2023 Aug 14, 2023	BUY	$8.48 - $16.48 $1.42 Million - $2.76 Million	167,714 Added 52.66%	486,195 $8.01 Million
Q1 2023 May 15, 2023	BUY	$6.41 - $9.95 $1.4 Million - $2.17 Million	218,484 Added 218.49%	318,481 $2.92 Million
Q4 2022 Feb 14, 2023	BUY	$5.02 - $10.0 $53,598 - $106,770	10,677 Added 11.95%	99,997 $715,000
Q3 2022 Nov 14, 2022	SELL	$2.57 - $7.31 $184,376 - $524,434	-71,742 Reduced 44.54%	89,320 $447,000
Q2 2022 Aug 15, 2022	BUY	$1.07 - $6.95 $79,570 - $516,836	74,365 Added 85.78%	161,062 $393,000
Q1 2022 May 16, 2022	SELL	$5.46 - $8.29 $189,347 - $287,488	-34,679 Reduced 28.57%	86,697 $592,000
Q4 2021 Feb 14, 2022	BUY	$7.34 - $11.18 $239,203 - $364,345	32,589 Added 36.7%	121,376 $980,000
Q3 2021 Nov 15, 2021	SELL	$6.49 - $9.91 $165,637 - $252,923	-25,522 Reduced 22.33%	88,787 $870,000
Q2 2021 Aug 16, 2021	BUY	$6.73 - $9.05 $7,685 - $10,335	1,142 Added 1.01%	114,309 $769,000
Q1 2021 May 17, 2021	BUY	$6.61 - $10.07 $161,654 - $246,271	24,456 Added 27.57%	113,167 $1.02 Million
Q4 2020 Feb 16, 2021	BUY	$5.03 - $7.95 $84,458 - $133,488	16,791 Added 23.35%	88,711 $593,000
Q3 2020 Nov 16, 2020	BUY	$5.02 - $8.98 $110,173 - $197,084	21,947 Added 43.92%	71,920 $363,000
Q2 2020 Aug 14, 2020	BUY	$7.25 - $11.75 $223,002 - $361,418	30,759 Added 160.09%	49,973 $404,000
Q1 2020 May 15, 2020	SELL	$4.06 - $10.64 $479,664 - $1.26 Million	-118,144 Reduced 86.01%	19,214 $153,000
Q4 2019 Feb 14, 2020	BUY	$3.34 - $7.7 $372,149 - $857,949	111,422 Added 429.6%	137,358 $1.04 Million
Q3 2019 Nov 14, 2019	SELL	$1.92 - $4.47 $12,224 - $28,460	-6,367 Reduced 19.71%	25,936 $107,000
Q2 2019 Aug 14, 2019	SELL	$1.09 - $3.19 $70,394 - $206,016	-64,582 Reduced 66.66%	32,303 $93,000
Q4 2018 Feb 14, 2019	SELL	$1.74 - $4.66 $42,551 - $113,960	-24,455 Reduced 20.15%	96,885 $249,000
Q3 2018 Nov 13, 2018	SELL	$4.08 - $7.14 $525,304 - $919,282	-128,751 Reduced 51.48%	121,340 $0
Q2 2018 Aug 10, 2018	BUY	$5.89 - $7.78 $761,812 - $1.01 Million	129,340 Added 107.11%	250,091 $0
Q1 2018 May 11, 2018	SELL	$6.76 - $11.7 $188,766 - $326,710	-27,924 Reduced 18.78%	120,751 $880,000
Q4 2017 Feb 09, 2018	BUY	$8.03 - $11.25 $430,456 - $603,067	53,606 Added 56.39%	148,675 $1.22 Million
Q3 2017 Nov 09, 2017	BUY	$8.35 - $10.5 $793,826 - $998,224	95,069	95,069 $998,000

Others Institutions Holding AVDL

# of Institutions

Shares Held

1.07M

Call Options Held

Put Options Held

View Full List

About AVADEL PHARMACEUTICALS PLC

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

More about AVDL

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account